CEO of Kalvista Pharmaceuticals Inc (30-Year Financial, Insider Trades) Thomas Andrew Crockett (insider trades) sold 38,539 shares of KALV on 10/21/2020 at an average price of $17.98 a share. The total sale was $692,931.
KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. KalVista Pharmaceuticals Inc has a market cap of $282.400 million; its shares were traded at around $15.77 with and P/S ratio of 30.20. KalVista Pharmaceuticals Inc had annual average EBITDA growth of 46.30% over the past five years. GuruFocus has detected 2 severe warning signs with KalVista Pharmaceuticals Inc. .
CEO Recent Trades:
- CEO Thomas Andrew Crockett sold 38,539 shares of KALV stock on 10/21/2020 at the average price of $17.98. The price of the stock has decreased by 12.29% since.
- CEO Thomas Andrew Crockett sold 1,261 shares of KALV stock on 10/16/2020 at the average price of $17.01. The price of the stock has decreased by 7.29% since.
Directors and Officers Recent Trades:
- Chief Development Officer Christopher Yea sold 13,986 shares of KALV stock on 10/21/2020 at the average price of $17.82. The price of the stock has decreased by 11.5% since.
- Chief Scientific Officer Edward P. Feener sold 16,907 shares of KALV stock on 10/21/2020 at the average price of $17.92. The price of the stock has decreased by 12% since.
- Chief Development Officer Christopher Yea sold 914 shares of KALV stock on 10/16/2020 at the average price of $17. The price of the stock has decreased by 7.24% since.
- Chief Scientific Officer Edward P. Feener sold 993 shares of KALV stock on 10/16/2020 at the average price of $17. The price of the stock has decreased by 7.24% since.
For the complete insider trading history of KALV, click here
.
